David McDermott

Dr. McDermott is Director of the Biologic Therapy and Cutaneous Oncology Programs at Beth Israel Deaconess Medical Center. He is Leader of the Dana Farber/Harvard Cancer Center Kidney Cancer Program and Principal Investigator of the NCI Kidney Cancer SPORE grant. Dr. McDermott is a clinical investigator with a particular interest in therapies that enhance the immune response to cancer. He has contributed to the rational application of interleukin-2 and immune check point inhibitors (CTLA-4, PD-1 antibodies) for renal cell carcinoma and melanoma. He has worked with anti-angiogenic agents and targeted therapeutics for these malignancies. He is Director of the Cytokine Working Group which has been a major innovator in the field of solid tumor immunotherapy. Dr. McDermott is Associate Professor of Medicine at Harvard Medical School.

Dr. McDermott earned his medical degree from Cornell University Medical College, followed by residency in internal medicine and fellowship in hematology/oncology at Tufts/New England Medical Center. Dr. McDermott has served on the Program Committee for the American Society of Clinical Oncology as well as the Medical Advisory Board for the Kidney Cancer Association. He serves on the NCI Kidney Cancer Task Force.